Human Rabies Immunoglobulin (IM) Market Size, Share, Growth, and Industry Analysis, By Type (ERIG,HRIG), By Application (Category II Exposure,Category III Exposure), Regional Insights and Forecast to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

HUMAN RABIES IMMUNOGLOBULIN (IM) MARKET OVERVIEW

Global Human Rabies Immunoglobulin (IM) market size is projected at USD 0.330 billion in 2026 and is anticipated to reach USD 0.445 billion by 2035, registering a CAGR of 3.4%.

The Human Rabies Immunoglobulin (IM) Market plays a critical role in post-exposure prophylaxis protocols for rabies management. Globally, rabies causes approximately 59,000 human deaths annually, with over 95% of cases occurring in Asia and Africa. Human rabies immunoglobulin (IM) is administered in Category III exposures, which represent nearly 35%–40% of reported rabies exposures worldwide. Around 29 million people receive post-exposure prophylaxis each year, creating strong demand for Human Rabies Immunoglobulin (IM) Market products. Production relies on plasma-derived antibodies collected from vaccinated donors, with global plasma collection centers exceeding 1,200 facilities across 40 countries. Human Rabies Immunoglobulin (IM) Market Analysis indicates that more than 60% of immunoglobulin distribution occurs through hospital pharmacies and trauma centers handling animal bite cases.

The Human Rabies Immunoglobulin (IM) Market in the United States represents a highly regulated segment within the immunoglobulin therapeutics industry. The U.S. records approximately 4,000 animal rabies cases annually, with wildlife accounting for nearly 92% of confirmed infections. Each year, an estimated 55,000 people in the U.S. receive rabies post-exposure prophylaxis, and approximately 12%–18% of those cases require Human Rabies Immunoglobulin (IM) administration. The country operates over 900 plasma collection centers, supporting a stable supply chain for HRIG production. The Human Rabies Immunoglobulin (IM) Industry Report highlights that hospital emergency departments handle nearly 70% of rabies exposure treatments, while infectious disease clinics contribute about 20% of HRIG administration.

KEY FINDINGS OF HUMAN RABIES IMMUNOGLOBULIN (IM) MARKET

• Key Market Driver: Approximately 72% of rabies exposures globally originate from dog bites, while 38% of post-exposure treatments require immunoglobulin therapy, and nearly 64% of healthcare systems prioritize immunoglobulin inclusion in rabies protocols, driving consistent demand across 85% of endemic regions.

• Major Market Restraint: Nearly 46% of low-income countries report immunoglobulin supply shortages, around 52% of treatment centers face affordability barriers, and 41% of hospitals rely on alternative protocols, reducing Human Rabies Immunoglobulin (IM) Market accessibility in several developing regions.

• Emerging Trends: Around 58% of vaccine manufacturers are integrating monoclonal antibody alternatives, while 36% of new rabies biologics pipelines involve recombinant technologies, and nearly 44% of clinical studies focus on reducing dosage volume through higher antibody concentrations.

• Regional Leadership: Asia-Pacific accounts for nearly 63% of global rabies exposure incidents, while 48% of immunoglobulin demand originates in Asian healthcare systems, followed by North America with approximately 21% usage and Europe contributing around 16% consumption.

• Competitive Landscape: The top 5 manufacturers control nearly 68% of global supply, while the top 10 companies collectively manage around 84% of production capacity, with plasma-derived immunoglobulin producers dominating nearly 76% of the Human Rabies Immunoglobulin (IM) Market share.

• Market Segmentation: Category III exposures account for approximately 72% of immunoglobulin administration, while Category II exposures represent nearly 28% of rabies prophylaxis procedures, and hospital-based treatments contribute nearly 66% of immunoglobulin usage globally.

• Recent Development: Approximately 47% of new immunoglobulin manufacturing facilities announced between 2023 and 2025 were located in Asia, while 33% of biologics investments targeted rabies antibody production, and 19% of pipeline developments involve improved purification technologies.

LATEST TRENDS

The Human Rabies Immunoglobulin (IM) Market Trends show increasing adoption of advanced plasma-derived antibody purification technologies. Globally, plasma fractionation capacity reached approximately 70 million liters annually, with more than 45 million liters dedicated to immunoglobulin production. Around 18% of total immunoglobulin output is allocated to infectious disease applications, including rabies prophylaxis. The Human Rabies Immunoglobulin (IM) Market Research Report highlights that Category III exposures require immediate HRIG infiltration in nearly 100% of severe bite cases, particularly when wounds occur on the head, neck, or hands, which account for approximately 34% of high-risk exposures.

Another significant trend involves expanding rabies control programs across developing economies. Government vaccination campaigns target approximately 70% dog vaccination coverage, which can reduce human rabies cases by nearly 80% in endemic areas. Despite these initiatives, about 15 million people annually receive Category III exposure treatment, sustaining demand for immunoglobulin products. The Human Rabies Immunoglobulin (IM) Market Outlook also indicates that healthcare facilities in more than 110 countries maintain rabies immunoglobulin stockpiles, while 36% of new production facilities under development are located in Asia-Pacific to address high exposure rates.

MARKET DYNAMICS

Driver

Rising incidence of rabies exposure and post-exposure prophylaxis demand

The Human Rabies Immunoglobulin (IM) Market Growth is strongly driven by increasing rabies exposure cases worldwide. Each year approximately 29 million people receive post-exposure prophylaxis, with nearly 40% requiring immunoglobulin administration due to Category III exposure. Dog bites account for about 99% of human rabies transmission cases, particularly in regions where vaccination coverage remains below 60%. The Human Rabies Immunoglobulin (IM) Market Analysis indicates that children under 15 years represent nearly 40% of rabies victims, increasing demand for emergency prophylaxis in pediatric healthcare systems. Additionally, over 150 countries report rabies risk, with more than 3 billion people living in endemic areas, reinforcing the need for immunoglobulin therapy.

Restraint

Limited availability and high production complexity of immunoglobulin products

A major challenge affecting the Human Rabies Immunoglobulin (IM) Market Size is the complex manufacturing process of plasma-derived immunoglobulins. HRIG production requires plasma collected from vaccinated donors, and each batch requires approximately 8–10 months of processing and quality testing. Globally, only about 35 major plasma fractionation facilities produce rabies immunoglobulin products. Supply limitations result in approximately 45% of endemic countries reporting shortages, particularly in rural healthcare centers. In addition, HRIG dosage requires around 20 IU per kilogram of body weight, meaning a 60 kg patient requires about 1,200 IU, creating cost and supply pressure for healthcare providers.

Expansion of plasma collection networks and biologics manufacturing

Opportunity

The Human Rabies Immunoglobulin (IM) Market Opportunities are expanding due to increasing plasma collection capacity and biologics investments. Worldwide plasma collection centers increased from approximately 850 facilities in 2015 to over 1,200 centers in 2024, supporting larger immunoglobulin supply chains. Emerging markets such as India and China collectively represent nearly 38% of global rabies exposure cases, encouraging governments to invest in domestic biologics manufacturing.

Several national health systems have initiated rabies elimination strategies targeting zero human deaths by 2030, increasing demand for immunoglobulin stockpiles. The Human Rabies Immunoglobulin (IM) Industry Analysis suggests that expanding hospital infrastructure and emergency treatment units in more than 60 developing countries will further increase HRIG accessibility.

Alternative biologics and monoclonal antibody therapies

Challenge

A growing challenge for the Human Rabies Immunoglobulin (IM) Market Share involves the development of monoclonal antibody therapies. Approximately 22 monoclonal rabies antibody candidates are currently under clinical investigation worldwide. These therapies aim to replace plasma-derived HRIG with synthetic antibodies capable of delivering neutralizing titers exceeding 0.5 IU/mL, which is the protective threshold recommended by international health guidelines.

Monoclonal antibody products require smaller doses and reduce dependency on donor plasma. Currently, around 18% of rabies biologics research funding is directed toward monoclonal antibody platforms, potentially reshaping the long-term structure of the Human Rabies Immunoglobulin (IM) Market Forecast.

•   
•   
  

  Download Free Sample to learn more about this report

    

HUMAN RABIES IMMUNOGLOBULIN (IM) MARKET SEGMENTATION

By Type

• ERIG: Equine Rabies Immunoglobulin (ERIG) accounts for approximately 60%–65% of global rabies immunoglobulin usage, particularly in developing regions with high rabies incidence. ERIG is derived from horse plasma immunized with rabies antigens and contains high concentrations of neutralizing antibodies. The Human Rabies Immunoglobulin (IM) Market Insights indicate that ERIG is widely used in Asia-Pacific, where nearly 75% of rabies prophylaxis treatments involve equine-derived antibodies. Each ERIG dose typically contains 40 IU per kilogram of body weight, double the dosage compared with HRIG due to lower antibody specificity. More than 120 million doses of ERIG have been distributed globally during the past decade, supporting rabies treatment programs in over 80 countries.

• HRIG: Human Rabies Immunoglobulin (HRIG) represents approximately 35% of the Human Rabies Immunoglobulin (IM) Market Size, mainly used in developed healthcare systems due to higher safety profiles and reduced hypersensitivity risk. HRIG contains purified antibodies derived from human plasma donors vaccinated with rabies antigen boosters. A typical HRIG dose requires 20 IU per kilogram of body weight, meaning a 70 kg adult requires approximately 1,400 IU. The Human Rabies Immunoglobulin (IM) Market Report highlights that HRIG products demonstrate hypersensitivity rates below 1%, compared with ERIG reactions ranging from 1% to 6%. North America and Europe collectively account for nearly 55% of HRIG consumption, reflecting higher regulatory standards and advanced biologics manufacturing infrastructure.

By Application

• Category II Exposure: Category II exposures include minor scratches or nibbling without bleeding and account for approximately 28%–30% of rabies exposure cases worldwide. These exposures typically require rabies vaccination without mandatory immunoglobulin infiltration. However, in some high-risk regions, around 12% of Category II cases receive preventive HRIG administration, especially when patient vaccination history is unknown. The Human Rabies Immunoglobulin (IM) Market Insights indicate that rural healthcare centers in Asia report nearly 3 million Category II exposure treatments annually, with vaccination campaigns targeting populations in over 50 high-risk districts.

• Category III Exposure: Category III exposures represent the most severe rabies exposure category and account for nearly 70%–72% of immunoglobulin administration globally. These exposures involve transdermal bites, scratches with bleeding, or mucosal contamination. The Human Rabies Immunoglobulin (IM) Market Outlook shows that approximately 15 million Category III exposure cases occur annually, requiring immediate immunoglobulin infiltration combined with vaccination. Children represent approximately 40% of Category III exposure victims, while dog bites account for nearly 90% of such incidents. Healthcare systems in Asia-Pacific administer nearly 65% of all Category III immunoglobulin treatments worldwide, reflecting the region’s higher rabies incidence rates.

•   
•   
  Download Free Sample to learn more about this report

    

HUMAN RABIES IMMUNOGLOBULIN (IM) MARKET REGIONAL OUTLOOK

• North America

North America accounts for approximately 21% of the Human Rabies Immunoglobulin (IM) Market Share, supported by strong healthcare infrastructure and high vaccination awareness. The United States reports around 4,000 rabies-positive animal cases annually, with raccoons representing nearly 30% of infections, bats accounting for 32%, and skunks contributing approximately 20%. Approximately 55,000 individuals receive rabies post-exposure prophylaxis each year in the U.S., with about 10,000 cases requiring HRIG treatment. Canada reports fewer than 20 human rabies cases in the last 50 years, but around 2,000 people annually receive prophylactic vaccination following wildlife exposure. The Human Rabies Immunoglobulin (IM) Market Analysis indicates that nearly 85% of HRIG treatments in North America occur in hospital emergency departments, while trauma centers account for about 10% of treatments. Government surveillance programs monitor over 120 wildlife species for rabies infection, maintaining early detection and immunoglobulin deployment strategies.

• Europe

Europe represents approximately 16% of the Human Rabies Immunoglobulin (IM) Market Size, with strict rabies control programs across more than 40 countries. Over 90% of European Union member states maintain wildlife vaccination campaigns targeting fox populations, reducing human rabies incidence significantly. Approximately 8,000 post-exposure prophylaxis treatments are administered annually across Western Europe, while Eastern Europe records nearly 12,000 cases per year. The Human Rabies Immunoglobulin (IM) Market Trends indicate that HRIG accounts for nearly 70% of immunoglobulin usage in Europe, reflecting advanced healthcare standards. Countries such as Germany, France, and the United Kingdom maintain centralized biologics stockpiles with immunoglobulin reserves sufficient for 6–12 months of emergency demand. Europe also operates approximately 60 plasma fractionation facilities, contributing significantly to global immunoglobulin production capacity.

• Asia-Pacific

Asia-Pacific dominates the Human Rabies Immunoglobulin (IM) Market Share, accounting for nearly 48%–50% of global immunoglobulin demand. The region records approximately 35,000 rabies deaths annually, representing more than 60% of global fatalities. India alone accounts for nearly 36% of global rabies deaths, while China reports approximately 150–200 human cases annually due to aggressive vaccination programs. The Human Rabies Immunoglobulin (IM) Market Outlook shows that more than 18 million people annually receive post-exposure prophylaxis in Asia, with approximately 7 million requiring immunoglobulin infiltration. Governments across 12 Asian countries have introduced national rabies elimination programs targeting 70% dog vaccination coverage. Additionally, Asia hosts more than 25 immunoglobulin manufacturing facilities, increasing regional supply capacity.

• Middle East & Africa

The Middle East & Africa region accounts for approximately 13%–15% of the Human Rabies Immunoglobulin (IM) Market, with Africa experiencing the highest rabies mortality rates. Approximately 21,000 human rabies deaths occur annually in Africa, representing nearly 36% of global fatalities. Countries such as Ethiopia, Nigeria, and Tanzania report thousands of exposure cases each year. The Human Rabies Immunoglobulin (IM) Market Research Report indicates that only 45% of healthcare facilities in sub-Saharan Africa maintain immunoglobulin stock, resulting in treatment gaps. Approximately 8 million people receive rabies vaccination annually across Africa, but fewer than 3 million cases receive immunoglobulin therapy due to supply limitations. Several international health initiatives aim to expand rabies prevention programs across 30 African countries.

LIST OF TOP HUMAN RABIES IMMUNOGLOBULIN (IM) COMPANIES

• CSL Behring
• Grifols
• Sanofi
• Sichuan Yuanda Shuyang
• Tiantan Bio
• Kamada
• CBPO
• Shuanglin Bio
• Weiguang Bio
• Shanghai RAAS
• Bharat Serum
• VINS

Top Two Companies By Market Share

• CSL Behring holds approximately 18% of global Human Rabies Immunoglobulin (IM) Market Share, supported by plasma collection networks exceeding 300 centers worldwide and biologics manufacturing facilities across 5 continents.
• Grifols accounts for nearly 15% of the Human Rabies Immunoglobulin (IM) Market Size, operating more than 390 plasma collection centers and producing immunoglobulin therapies distributed in over 100 countries.

INVESTMENT ANALYSIS AND OPPORTUNITIES

The Human Rabies Immunoglobulin (IM) Market Opportunities are expanding as governments and biologics manufacturers increase investment in plasma fractionation and infectious disease prevention programs. Global plasma collection capacity surpassed 70 million liters annually, enabling larger production volumes for immunoglobulin therapies. Approximately 25 new plasma collection centers were opened between 2023 and 2024, supporting immunoglobulin manufacturing pipelines. Several emerging economies have increased biologics infrastructure investments to address rabies exposure cases. India alone reports nearly 20 million dog bite incidents annually, creating demand for millions of immunoglobulin doses. China operates more than 30 biologics manufacturing plants, with several facilities expanding antibody purification lines. The Human Rabies Immunoglobulin (IM) Industry Analysis highlights that approximately 40% of biologics investments in infectious disease therapeutics target antibody-based therapies.

International health programs also allocate significant funding to rabies elimination initiatives targeting zero human rabies deaths by 2030, encouraging governments to maintain immunoglobulin stockpiles. Approximately 150 countries participate in global rabies control programs, with immunoglobulin procurement forming a critical component of national treatment guidelines.

NEW PRODUCT DEVELOPMENT

Innovation within the Human Rabies Immunoglobulin (IM) Market focuses on improving antibody purification efficiency and enhancing neutralizing potency. Modern plasma fractionation technologies achieve antibody purity levels exceeding 98%, reducing contamination risk and improving clinical safety. Manufacturers are also developing high-concentration HRIG formulations, allowing smaller injection volumes during wound infiltration procedures. Another innovation trend involves the development of recombinant monoclonal antibody combinations designed to replace plasma-derived immunoglobulins. Over 20 monoclonal rabies antibody candidates are currently under clinical evaluation, with neutralizing titers exceeding 0.5 IU/mL, the recommended protective threshold. Some formulations combine 2 monoclonal antibodies targeting different rabies virus epitopes, improving viral neutralization efficiency.

Manufacturers are also improving cold-chain stability. Current HRIG products require storage between 2°C and 8°C, but new stabilization techniques allow products to remain stable for up to 36 months, compared with 24-month shelf life for traditional formulations. The Human Rabies Immunoglobulin (IM) Market Forecast indicates that improved formulations could increase immunoglobulin availability in remote healthcare facilities lacking advanced storage infrastructure.

FIVE RECENT DEVELOPMENTS (2023-2025)

• In 2023, a global biologics manufacturer expanded plasma fractionation capacity by 500,000 liters annually, increasing immunoglobulin production output by approximately 12%.
• In 2023, a biotechnology company initiated Phase III clinical trials involving over 800 participants for a monoclonal antibody therapy designed to replace HRIG in rabies prophylaxis.
• In 2024, a pharmaceutical company upgraded an immunoglobulin purification facility, increasing antibody recovery efficiency from 75% to 90% during plasma processing.
• In 2024, a vaccine manufacturer partnered with 15 national health agencies to distribute rabies immunoglobulin treatments in regions reporting more than 500,000 exposure cases annually.
• In 2025, a biologics firm introduced a high-concentration HRIG formulation containing 300 IU/mL antibodies, reducing injection volume by nearly 35% compared with traditional products.

HUMAN RABIES IMMUNOGLOBULIN (IM) MARKET REPORT COVERAGE

The Human Rabies Immunoglobulin (IM) Market Report provides comprehensive insights into global immunoglobulin production, rabies exposure statistics, and biologics manufacturing trends. The report analyzes data from more than 150 countries where rabies exposure risk exists and examines healthcare systems treating approximately 29 million post-exposure prophylaxis cases annually. The Human Rabies Immunoglobulin (IM) Industry Report evaluates treatment protocols for Category II and Category III exposures, including antibody dosage requirements such as 20 IU/kg for HRIG and 40 IU/kg for ERIG.

The report also examines plasma collection infrastructure, covering more than 1,200 plasma donation centers globally and analyzing fractionation capacity exceeding 70 million liters of plasma per year. Additionally, the Human Rabies Immunoglobulin (IM) Market Research Report assesses regulatory frameworks across 40 major pharmaceutical markets, evaluating immunoglobulin approval standards and distribution networks. Market coverage includes hospital pharmacies, emergency departments, infectious disease clinics, and vaccination centers responsible for delivering rabies prophylaxis to millions of patients annually.